Saturday, October 5 2024

Breaking News

ESMO’22 Recommended Abstracts in RENAL CANCERS
Gene activity Can Provide Clues for Risk of Kidney Cancer Spreading
A 20-year retrospective: How Kidney Cancer Journal Reflected on Advances in The Therapeutic Strategies
2022 ESMO: Promise and Pitfalls of Adjuvant Immunotherapy
Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors
Kidney Cancer Research Highlights from ASCO 2022 Annual Meeting
Engineered T-Cell Therapy: The Next Direction for RCC Immuno-oncology?
Comparison of Papillary Renal Cell Carcinoma Type 1 and Type 2: A Secondary Data Analysis
Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma
From Gene Discovery to a FDA approval; Belzutifan’s Fascinating Journey at UTSW

Switch skin
Sidebar
Random Article

Menu

Search for

Home
Cancer
Spotlight
Conferences
Clinical Trials
FDA News
COVID-19 & cancer
Guidelines
- UroWeb guide
- EU Oncology
Resource Center
- Urosource
Opinion
- NEWS
- Media
- CME/CE

Search for
Follow

Home/FDA/Drug Updates

FDA/Drug Updates

Share

Facebook Twitter LinkedIn Tumblr Pinterest Reddit Share via Email Print

Home
About Us
Subscribe GUcancers
Submission Guidelines
eNewslette Sign-Up
Contact Us
Privacy Policy & Disclaimer
Site Map

Home
About Us
Subscribe GUcancers
Submission Guidelines
eNewslette Sign-Up
Contact Us
Privacy Policy & Disclaimer
Site Map

Advertising Policy
Editorial policy
Term & Conditions

Subscribe

Email Address *

Error Can not Get Tweets, Incorrect account info.

You need to install the TieLabs Instagram Feed plugin to use this feature.

Search

Search for:

© Copyright 2021-22, All Rights Reserved | Biomedz Global LLC GUcancers does not provide medical advice, diagnosis or treatment. See additional information

Back to top button

Close

Search for:

Search

Search for:

Recent Posts

ESMO’22 Recommended Abstracts in RENAL CANCERS
Gene activity Can Provide Clues for Risk of Kidney Cancer Spreading
A 20-year retrospective: How Kidney Cancer Journal Reflected on Advances in The Therapeutic Strategies
2022 ESMO: Promise and Pitfalls of Adjuvant Immunotherapy
Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors

Recent Comments